STAAR Surgical Company

STAA · NasdaqGM · Stock · Healthcare
$22.32
+2.20% today
Delayed price,

What STAAR Surgical does

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Key facts

Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$1.12B
P/E (ttm)
279.0
Forward P/E
20.1
Dividend yield
0.00%
Beta
1.18
Profit margin
1.1%
Employees
921
Headquarters
Lake Forest, CA, United States
Exchange
NasdaqGM

Performance

1 Month
+7.2%
3 Months
-15.6%
6 Months
-11.0%
1 Year
-10.8%
5 Years
-76.6%
$15.5952-week range$35.87
Biggest setback — last 12 months
-42.5%
17 Nov 2025 → 9 Feb 2026
Fell from $28.00 to $16.10 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+101.7%
9 Feb 2026 → 18 May 2026
Ran from $16.10 to $32.47 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend
Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$19.19 (-14.0%)$22.32$25.96 (+16.3%)
3 Months$17.18 (-23.0%)$22.32$29.00 (+29.9%)
6 Months$15.41 (-31.0%)$22.32$32.33 (+44.8%)
12 Months$13.22 (-40.8%)$22.32$37.69 (+68.9%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 52.4%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent insider activity

Sold 16,592 shares at $26.18 — Foust Warren, President and CEO · 2026-08-18
Sold 7,895 shares at $26.18 — ANDREWS DEBORAH J, Chief Financial Officer & EVP · 2026-08-18
Acquired 9,955 shares at $26.18 — Michna Magda, Chief Development Officer · 2026-08-18
Sold 31,363 shares at $24.36 — Foust Warren, President and CEO · 2026-08-04
Sold 51,798 shares at $24.36 — ANDREWS DEBORAH J, Chief Financial Officer & EVP · 2026-08-04
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.